Effectiveness of Convalescent Immune Plasma Therapy

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 15, 2020

Primary Completion Date

June 15, 2020

Study Completion Date

June 17, 2020

Conditions
Acute Respiratory Distress Syndrome
Interventions
OTHER

Convalescent Immune Plasma

One dose of 200 mL of convalescent ımmune plasma derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to standart critical care treatment.

Trial Locations (1)

34375

Istanbul Bagcılar Training and Research Hospital, Istanbul

All Listed Sponsors
lead

Bagcilar Training and Research Hospital

OTHER_GOV

NCT04442958 - Effectiveness of Convalescent Immune Plasma Therapy | Biotech Hunter | Biotech Hunter